Oncolytic virotherapy for pancreatic cancer.

Sonia Wennier, Shoudong Li, Grant McFadden

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Within the past decade, many oncolytic viruses (OVs) have been studied as potential treatments for pancreatic cancer and some of these are currently under clinical trials. The applicability of certain OVs, such as adenoviruses, herpesviruses and reoviruses, for the treatment of pancreatic cancer has been intensively studied for several years, whereas the applicability of other more recently investigated OVs, such as poxviruses and parvoviruses, is only starting to be determined. At the same time, studies have identified key characteristics of pancreatic cancer biology that provide a better understanding of the important factors or pathways involved in this disease. This review aims to summarise the different replication-competent OVs proposed as therapeutics for pancreatic cancer. It also focuses on the unique biology of these viruses that makes them exciting candidate virotherapies for pancreatic cancer and discusses how they could be genetically manipulated or combined with other drugs to improve their efficacy based on what is currently known about the molecular biology of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)e18
JournalExpert reviews in molecular medicine
StatePublished - 2011
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology


Dive into the research topics of 'Oncolytic virotherapy for pancreatic cancer.'. Together they form a unique fingerprint.

Cite this